Global Chimeric Antigen Receptor T Cell Therapy Market Research Report 2023

The global Chimeric Antigen Receptor T Cell Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Chimeric Antigen Receptor T Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Chimeric Antigen Receptor T Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Chimeric Antigen Receptor T Cell Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Chimeric Antigen Receptor T Cell Therapy include Amgen, Bellicum Pharmaceuticals, Bluebird Bio, Caribou Biosciences, Celgene Corporation, Cellectis, Celyad Oncology, Gilead Sciences and Intellia Therapeutics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Chimeric Antigen Receptor T Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chimeric Antigen Receptor T Cell Therapy.

The Chimeric Antigen Receptor T Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chimeric Antigen Receptor T Cell Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chimeric Antigen Receptor T Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Allogeneic

1.2.3 Autologous

1.3 Market by Application

1.3.1 Global Chimeric Antigen Receptor T Cell Therapy Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Universities and Colleges

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Perspective (2018-2029)

2.2 Chimeric Antigen Receptor T Cell Therapy Growth Trends by Region

2.2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Region (2018-2023)

2.2.3 Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Region (2024-2029)

2.3 Chimeric Antigen Receptor T Cell Therapy Market Dynamics

2.3.1 Chimeric Antigen Receptor T Cell Therapy Industry Trends

2.3.2 Chimeric Antigen Receptor T Cell Therapy Market Drivers

2.3.3 Chimeric Antigen Receptor T Cell Therapy Market Challenges

2.3.4 Chimeric Antigen Receptor T Cell Therapy Market Restraints

3.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue

3.1.1 Global Top Chimeric Antigen Receptor T Cell Therapy Players by Revenue (2018-2023)

3.1.2 Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Players (2018-2023)

3.2 Global Chimeric Antigen Receptor T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Chimeric Antigen Receptor T Cell Therapy Revenue

3.4 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio

3.4.1 Global Chimeric Antigen Receptor T Cell Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chimeric Antigen Receptor T Cell Therapy Revenue in 2022

3.5 Chimeric Antigen Receptor T Cell Therapy Key Players Head office and Area Served

3.6 Key Players Chimeric Antigen Receptor T Cell Therapy Product Solution and Service

3.7 Date of Enter into Chimeric Antigen Receptor T Cell Therapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Type (2018-2023)

4.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Type (2024-2029)

5.1 Global Chimeric Antigen Receptor T Cell Therapy Historic Market Size by Application (2018-2023)

5.2 Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Application (2024-2029)

6.1 North America Chimeric Antigen Receptor T Cell Therapy Market Size (2018-2029)

6.2 North America Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023)

6.4 North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Chimeric Antigen Receptor T Cell Therapy Market Size (2018-2029)

7.2 Europe Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023)

7.4 Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size (2018-2029)

8.2 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2018-2023)

8.4 Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size (2018-2029)

9.2 Latin America Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023)

9.4 Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size (2018-2029)

10.2 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023)

10.4 Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Amgen

11.1.1 Amgen Company Detail

11.1.2 Amgen Business Overview

11.1.3 Amgen Chimeric Antigen Receptor T Cell Therapy Introduction

11.1.4 Amgen Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.1.5 Amgen Recent Development

11.2 Bellicum Pharmaceuticals

11.2.1 Bellicum Pharmaceuticals Company Detail

11.2.2 Bellicum Pharmaceuticals Business Overview

11.2.3 Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Introduction

11.2.4 Bellicum Pharmaceuticals Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.2.5 Bellicum Pharmaceuticals Recent Development

11.3 Bluebird Bio

11.3.1 Bluebird Bio Company Detail

11.3.2 Bluebird Bio Business Overview

11.3.3 Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Introduction

11.3.4 Bluebird Bio Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.3.5 Bluebird Bio Recent Development

11.4 Caribou Biosciences

11.4.1 Caribou Biosciences Company Detail

11.4.2 Caribou Biosciences Business Overview

11.4.3 Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Introduction

11.4.4 Caribou Biosciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.4.5 Caribou Biosciences Recent Development

11.5 Celgene Corporation

11.5.1 Celgene Corporation Company Detail

11.5.2 Celgene Corporation Business Overview

11.5.3 Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Introduction

11.5.4 Celgene Corporation Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.5.5 Celgene Corporation Recent Development

11.6 Cellectis

11.6.1 Cellectis Company Detail

11.6.2 Cellectis Business Overview

11.6.3 Cellectis Chimeric Antigen Receptor T Cell Therapy Introduction

11.6.4 Cellectis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.6.5 Cellectis Recent Development

11.7 Celyad Oncology

11.7.1 Celyad Oncology Company Detail

11.7.2 Celyad Oncology Business Overview

11.7.3 Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Introduction

11.7.4 Celyad Oncology Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.7.5 Celyad Oncology Recent Development

11.8 Gilead Sciences

11.8.1 Gilead Sciences Company Detail

11.8.2 Gilead Sciences Business Overview

11.8.3 Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Introduction

11.8.4 Gilead Sciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.8.5 Gilead Sciences Recent Development

11.9 Intellia Therapeutics

11.9.1 Intellia Therapeutics Company Detail

11.9.2 Intellia Therapeutics Business Overview

11.9.3 Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction

11.9.4 Intellia Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.9.5 Intellia Therapeutics Recent Development

11.10 Johnson & Johnson

11.10.1 Johnson & Johnson Company Detail

11.10.2 Johnson & Johnson Business Overview

11.10.3 Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Introduction

11.10.4 Johnson & Johnson Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.10.5 Johnson & Johnson Recent Development

11.11 Legend Biotech

11.11.1 Legend Biotech Company Detail

11.11.2 Legend Biotech Business Overview

11.11.3 Legend Biotech Chimeric Antigen Receptor T Cell Therapy Introduction

11.11.4 Legend Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.11.5 Legend Biotech Recent Development

11.12 Merck

11.12.1 Merck Company Detail

11.12.2 Merck Business Overview

11.12.3 Merck Chimeric Antigen Receptor T Cell Therapy Introduction

11.12.4 Merck Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.12.5 Merck Recent Development

11.13 Noile-Immune Biotech

11.13.1 Noile-Immune Biotech Company Detail

11.13.2 Noile-Immune Biotech Business Overview

11.13.3 Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Introduction

11.13.4 Noile-Immune Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.13.5 Noile-Immune Biotech Recent Development

11.14 Novartis

11.14.1 Novartis Company Detail

11.14.2 Novartis Business Overview

11.14.3 Novartis Chimeric Antigen Receptor T Cell Therapy Introduction

11.14.4 Novartis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.14.5 Novartis Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Detail

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Chimeric Antigen Receptor T Cell Therapy Introduction

11.15.4 Pfizer Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.15.5 Pfizer Recent Development

11.16 Sangamo Therapeutics

11.16.1 Sangamo Therapeutics Company Detail

11.16.2 Sangamo Therapeutics Business Overview

11.16.3 Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Introduction

11.16.4 Sangamo Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.16.5 Sangamo Therapeutics Recent Development

11.17 Servier Laboratories

11.17.1 Servier Laboratories Company Detail

11.17.2 Servier Laboratories Business Overview

11.17.3 Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Introduction

11.17.4 Servier Laboratories Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

11.17.5 Servier Laboratories Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Allogeneic

    Table 3. Key Players of Autologous

    Table 4. Global Chimeric Antigen Receptor T Cell Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2018-2023)

    Table 8. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2024-2029)

    Table 10. Chimeric Antigen Receptor T Cell Therapy Market Trends

    Table 11. Chimeric Antigen Receptor T Cell Therapy Market Drivers

    Table 12. Chimeric Antigen Receptor T Cell Therapy Market Challenges

    Table 13. Chimeric Antigen Receptor T Cell Therapy Market Restraints

    Table 14. Global Chimeric Antigen Receptor T Cell Therapy Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Players (2018-2023)

    Table 16. Global Top Chimeric Antigen Receptor T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor T Cell Therapy as of 2022)

    Table 17. Ranking of Global Top Chimeric Antigen Receptor T Cell Therapy Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Chimeric Antigen Receptor T Cell Therapy Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Chimeric Antigen Receptor T Cell Therapy Product Solution and Service

    Table 21. Date of Enter into Chimeric Antigen Receptor T Cell Therapy Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Type (2018-2023)

    Table 25. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Type (2024-2029)

    Table 27. Global Chimeric Antigen Receptor T Cell Therapy Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Application (2018-2023)

    Table 29. Global Chimeric Antigen Receptor T Cell Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share by Application (2024-2029)

    Table 31. North America Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Amgen Company Detail

    Table 47. Amgen Business Overview

    Table 48. Amgen Chimeric Antigen Receptor T Cell Therapy Product

    Table 49. Amgen Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 50. Amgen Recent Development

    Table 51. Bellicum Pharmaceuticals Company Detail

    Table 52. Bellicum Pharmaceuticals Business Overview

    Table 53. Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Product

    Table 54. Bellicum Pharmaceuticals Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 55. Bellicum Pharmaceuticals Recent Development

    Table 56. Bluebird Bio Company Detail

    Table 57. Bluebird Bio Business Overview

    Table 58. Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Product

    Table 59. Bluebird Bio Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 60. Bluebird Bio Recent Development

    Table 61. Caribou Biosciences Company Detail

    Table 62. Caribou Biosciences Business Overview

    Table 63. Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Product

    Table 64. Caribou Biosciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 65. Caribou Biosciences Recent Development

    Table 66. Celgene Corporation Company Detail

    Table 67. Celgene Corporation Business Overview

    Table 68. Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Product

    Table 69. Celgene Corporation Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 70. Celgene Corporation Recent Development

    Table 71. Cellectis Company Detail

    Table 72. Cellectis Business Overview

    Table 73. Cellectis Chimeric Antigen Receptor T Cell Therapy Product

    Table 74. Cellectis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 75. Cellectis Recent Development

    Table 76. Celyad Oncology Company Detail

    Table 77. Celyad Oncology Business Overview

    Table 78. Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Product

    Table 79. Celyad Oncology Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 80. Celyad Oncology Recent Development

    Table 81. Gilead Sciences Company Detail

    Table 82. Gilead Sciences Business Overview

    Table 83. Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Product

    Table 84. Gilead Sciences Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 85. Gilead Sciences Recent Development

    Table 86. Intellia Therapeutics Company Detail

    Table 87. Intellia Therapeutics Business Overview

    Table 88. Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Product

    Table 89. Intellia Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 90. Intellia Therapeutics Recent Development

    Table 91. Johnson & Johnson Company Detail

    Table 92. Johnson & Johnson Business Overview

    Table 93. Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Product

    Table 94. Johnson & Johnson Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 95. Johnson & Johnson Recent Development

    Table 96. Legend Biotech Company Detail

    Table 97. Legend Biotech Business Overview

    Table 98. Legend Biotech Chimeric Antigen Receptor T Cell Therapy Product

    Table 99. Legend Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 100. Legend Biotech Recent Development

    Table 101. Merck Company Detail

    Table 102. Merck Business Overview

    Table 103. Merck Chimeric Antigen Receptor T Cell Therapy Product

    Table 104. Merck Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 105. Merck Recent Development

    Table 106. Noile-Immune Biotech Company Detail

    Table 107. Noile-Immune Biotech Business Overview

    Table 108. Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Product

    Table 109. Noile-Immune Biotech Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 110. Noile-Immune Biotech Recent Development

    Table 111. Novartis Company Detail

    Table 112. Novartis Business Overview

    Table 113. Novartis Chimeric Antigen Receptor T Cell Therapy Product

    Table 114. Novartis Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 115. Novartis Recent Development

    Table 116. Pfizer Company Detail

    Table 117. Pfizer Business Overview

    Table 118. Pfizer Chimeric Antigen Receptor T Cell Therapy Product

    Table 119. Pfizer Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 120. Pfizer Recent Development

    Table 121. Sangamo Therapeutics Company Detail

    Table 122. Sangamo Therapeutics Business Overview

    Table 123. Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Product

    Table 124. Sangamo Therapeutics Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 125. Sangamo Therapeutics Recent Development

    Table 126. Servier Laboratories Company Detail

    Table 127. Servier Laboratories Business Overview

    Table 128. Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Product

    Table 129. Servier Laboratories Revenue in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023) & (US$ Million)

    Table 130. Servier Laboratories Recent Development

    Table 131. Research Programs/Design for This Report

    Table 132. Key Data Information from Secondary Sources

    Table 133. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Chimeric Antigen Receptor T Cell Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Type: 2022 VS 2029

    Figure 3. Allogeneic Features

    Figure 4. Autologous Features

    Figure 5. Global Chimeric Antigen Receptor T Cell Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Application: 2022 VS 2029

    Figure 7. Hospitals Case Studies

    Figure 8. Universities and Colleges Case Studies

    Figure 9. Others Case Studies

    Figure 10. Chimeric Antigen Receptor T Cell Therapy Report Years Considered

    Figure 11. Global Chimeric Antigen Receptor T Cell Therapy Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 12. Global Chimeric Antigen Receptor T Cell Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Region: 2022 VS 2029

    Figure 14. Global Chimeric Antigen Receptor T Cell Therapy Market Share by Players in 2022

    Figure 15. Global Top Chimeric Antigen Receptor T Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chimeric Antigen Receptor T Cell Therapy as of 2022)

    Figure 16. The Top 10 and 5 Players Market Share by Chimeric Antigen Receptor T Cell Therapy Revenue in 2022

    Figure 17. North America Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 18. North America Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2018-2029)

    Figure 19. United States Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Canada Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2018-2029)

    Figure 23. Germany Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. France Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. U.K. Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Italy Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Russia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Nordic Countries Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Chimeric Antigen Receptor T Cell Therapy Market Share by Region (2018-2029)

    Figure 31. China Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Japan Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. South Korea Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Southeast Asia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. India Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Australia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2018-2029)

    Figure 39. Mexico Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Brazil Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Market Share by Country (2018-2029)

    Figure 43. Turkey Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Saudi Arabia Chimeric Antigen Receptor T Cell Therapy Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Amgen Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 46. Bellicum Pharmaceuticals Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 47. Bluebird Bio Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 48. Caribou Biosciences Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 49. Celgene Corporation Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 50. Cellectis Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 51. Celyad Oncology Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 52. Gilead Sciences Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 53. Intellia Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 54. Johnson & Johnson Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 55. Legend Biotech Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 56. Merck Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 57. Noile-Immune Biotech Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 58. Novartis Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 59. Pfizer Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 60. Sangamo Therapeutics Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 61. Servier Laboratories Revenue Growth Rate in Chimeric Antigen Receptor T Cell Therapy Business (2018-2023)

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed